Javier Cortes

Summary

Publications

  1. doi request reprint Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 tr
    Javier Cortes
    Vall d Hebron Institute of Oncology, Barcelona, Spain and Ramon y Cajal University Hospital, Madrid, Spain Electronic address
    Lancet Oncol 16:1700-10. 2015
  2. pmc Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
    Chris Twelves
    Leeds Institute of Cancer and Pathology and St James s Institute of Oncology, Leeds, UK
    Breast Cancer Res Treat 148:553-61. 2014
  3. pmc Expert perspectives on biosimilar monoclonal antibodies in breast cancer
    J Cortes
    Department of Oncology, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, 08035, Barcelona, Spain
    Breast Cancer Res Treat 144:233-9. 2014
  4. pmc Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?
    Jose Perez-Garcia
    Breast Cancer Unit, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Breast Cancer Res 14:104. 2012
  5. doi request reprint Docetaxel combined with targeted therapies in metastatic breast cancer
    Javier Cortes
    Department of Oncology, Vall d Hebron University Hospital, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Cancer Treat Rev 38:387-96. 2012
  6. pmc Beyond taxanes: the next generation of microtubule-targeting agents
    Javier Cortes
    Breast Cancer Program, Department of Oncology, Vall d Hebron University Hospital, Vall d Hebron 119 129, Barcelona, Spain
    Breast Cancer Res Treat 133:821-30. 2012
  7. doi request reprint Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
    J Cortes
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 23:1130-7. 2012
  8. doi request reprint Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer
    Javier Cortes
    Department of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Treat Rev 38:143-51. 2012
  9. doi request reprint Multidisciplinary approach to breast cancer diagnosed during pregnancy: maternal and neonatal outcomes
    Octavi Córdoba
    Vall d Hebron Breast Cancer Center, Service of Gynecology, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Breast 22:515-9. 2013
  10. doi request reprint Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
    Javier Cortes
    Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 28:3922-8. 2010

Detail Information

Publications56

  1. doi request reprint Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 tr
    Javier Cortes
    Vall d Hebron Institute of Oncology, Barcelona, Spain and Ramon y Cajal University Hospital, Madrid, Spain Electronic address
    Lancet Oncol 16:1700-10. 2015
    ....
  2. pmc Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
    Chris Twelves
    Leeds Institute of Cancer and Pathology and St James s Institute of Oncology, Leeds, UK
    Breast Cancer Res Treat 148:553-61. 2014
    ..Eribulin improves OS in various patient subgroups with advanced/metastatic breast cancer who had previously received an anthracycline and a taxane. Women with HER2-negative disease are among those who may obtain benefit from eribulin...
  3. pmc Expert perspectives on biosimilar monoclonal antibodies in breast cancer
    J Cortes
    Department of Oncology, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, 08035, Barcelona, Spain
    Breast Cancer Res Treat 144:233-9. 2014
    ..Due to the abbreviated approval pathway, rigorous pharmacovigilance must be in place once a biosimilar mAb is approved in order to ensure its long-term safety and efficacy...
  4. pmc Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?
    Jose Perez-Garcia
    Breast Cancer Unit, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Breast Cancer Res 14:104. 2012
    ..For this reason, the Ki67 index might help to better define the group of patients who could have the optimal benefit...
  5. doi request reprint Docetaxel combined with targeted therapies in metastatic breast cancer
    Javier Cortes
    Department of Oncology, Vall d Hebron University Hospital, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Cancer Treat Rev 38:387-96. 2012
    ..Overall, docetaxel in combination with novel targeted agents in MBC appears to be highly active in patients with MBC, and such combinations represent promising treatment regimens for clinical investigation...
  6. pmc Beyond taxanes: the next generation of microtubule-targeting agents
    Javier Cortes
    Breast Cancer Program, Department of Oncology, Vall d Hebron University Hospital, Vall d Hebron 119 129, Barcelona, Spain
    Breast Cancer Res Treat 133:821-30. 2012
    ..The development of new microtubule-targeting agents helps to address the need for additional effective regimens for patients progressing after standard treatment with anthracycline- and taxane-containing regimens...
  7. doi request reprint Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
    J Cortes
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 23:1130-7. 2012
    ..A systematic review and meta-analysis was conducted to determine the risk of the most clinically relevant adverse outcomes associated with the use of bevacizumab in the treatment of breast cancer...
  8. doi request reprint Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer
    Javier Cortes
    Department of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Treat Rev 38:143-51. 2012
    ....
  9. doi request reprint Multidisciplinary approach to breast cancer diagnosed during pregnancy: maternal and neonatal outcomes
    Octavi Córdoba
    Vall d Hebron Breast Cancer Center, Service of Gynecology, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Breast 22:515-9. 2013
    ..We assessed maternal and neonatal outcome in women diagnosed with breast cancer during pregnancy...
  10. doi request reprint Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
    Javier Cortes
    Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 28:3922-8. 2010
    ....
  11. doi request reprint Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
    Javier Cortes
    Vall d Hebron University Hospital, Vall d Hebron Institute of Oncology, Barcelona, Spain
    Lancet 377:914-23. 2011
    ..Eribulin mesilate is a non-taxane microtubule dynamics inhibitor with a novel mode of action. We aimed to compare overall survival of heavily pretreated patients receiving eribulin versus currently available treatments...
  12. doi request reprint Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis
    Octavi Córdoba
    Breast Cancer Unit, Service of Gynecology, Hospital Vall d Hebron, Barcelona, Spain
    Breast 21:272-5. 2012
    ..009). Breast cancer patients presented a high number of unwanted pregnancies. Pregnancy after breast cancer not only did not adversely affect prognosis of the neoplasm but also may have a protective effect...
  13. doi request reprint Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma
    Mireia Caralt
    Department of Hepatobiliopancreatic Surgery and Transplants, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Hepatobiliary Pancreat Sci 18:268-75. 2011
    ..The aim of this study was to analyze the outcome of patients undergoing hepatic resection for melanoma liver metastases...
  14. doi request reprint Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis
    Davis Torrejón
    Breast Cancer Center, Vall d Hebron University Hospital, Passeig de la Vall d Hebron 119 129, 08035 Barcelona, Spain
    Breast 22:19-23. 2013
    ..We aimed to study the implications of breast cancer (BC) subtypes for the development and prognosis of leptomeningeal carcinomatosis (LC)...
  15. doi request reprint Safety of bevacizumab in metastatic breast cancer patients undergoing surgery
    Javier Cortes
    Department of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Eur J Cancer 48:475-81. 2012
    ..Evaluate the safety of surgery in relation to bevacizumab in the first-line treatment of metastatic breast cancer (mBC) in two international trials...
  16. pmc Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
    Javier Cortes
    Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain
    Breast Cancer Res Treat 154:509-20. 2015
    ..Patients receiving eribulin reported worse systemic side-effects of chemotherapy but reduced gastrointestinal toxicity compared with capecitabine...
  17. ncbi request reprint Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation
    Juan A Diaz-Gonzalez
    Department of Oncology, Clinica Universitaria, University of Navarra, Navarra, Spain
    Int J Radiat Oncol Biol Phys 64:1122-8. 2006
    ..Potential predictive factors for response and disease-free survival, with intense local multidisciplinary approach, are analyzed...
  18. ncbi request reprint Complete pathological remission in a patient with hormone-receptor positive and c-erbB-2 expression-negative breast cancer treated with FAC chemotherapy during pregnancy
    Octavi Córdoba
    Breast Unit, Service of Obstetrics and Gynecology, Hospital Vail d Hebron, Autonomous University of Barcelona, Barcelona, Spain
    Tumori 96:629-32. 2010
    ..This case illustrates how the integrated work of different specialists can obtain excellent oncological and obstetrical results in the care of pregnant women with breast cancer...
  19. doi request reprint Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast
    Maria Vidal
    Translational Genomics Group, Vall d Hebron Institute of Oncology VHIO, Pg Vall d Hebron, 119 129, 08035, Barcelona, Spain Breast Cancer Unit, Department of Medical Oncology, Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain
    Mol Oncol 9:1081-90. 2015
    ..Our results suggest that classification of FTs using gene expression-based data is feasible and might provide clinically useful biological and prognostic information...
  20. doi request reprint Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer
    Leticia De Mattos-Arruda
    Medical Oncology Department, Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Adv Ther 30:645-58. 2013
    ..Pertuzumab, a HER2-targeted monoclonal antibody that prevents HER2 dimerisation, is the first of a class of promising targeted agents for the treatment of HER2-positive breast cancer...
  21. doi request reprint Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer
    Javier Cortes
    Department of Medical Oncology, Breast Cancer Unit, Vall d Hebron University Hospital, 08035 Barcelona, Spain
    Future Oncol 7:355-64. 2011
    ..In addition, eribulin has a manageable tolerability profile, requires no premedication and has shorter infusion times than most other microtubule-targeted agents...
  22. doi request reprint Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain
    Carmen Frias
    Corporacio Sanitaria Parc Tauli, Barcelona, Spain
    Clin Transl Oncol 12:692-700. 2010
    ..Our aim was to evaluate the cost-effectiveness of docetaxel versus weekly paclitaxel regimen in patients with metastatic breast cancer previously treated with anthracycline from the Spanish National Health Service (NHS) perspective...
  23. doi request reprint Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
    Jose Baselga
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, Barcelona, Spain E 08035
    J Clin Oncol 28:1138-44. 2010
    ..This phase II trial assessed the efficacy and safety profile of the combination in patients with HER2-positive breast cancer whose disease had progressed during prior trastuzumab-based therapy...
  24. doi request reprint High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy
    Paolo Nuciforo
    Molecular Oncology Laboratory, Vall d Hebron Institute of Oncology, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain Universitat Autònoma de Barcelona, Placa Civica, 08193 Bellaterra Cerdanyola del Valles, Spain Electronic address
    Mol Oncol 10:138-47. 2016
    ..Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti-HER2 treatments...
  25. doi request reprint Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
    Leticia De Mattos-Arruda
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, P Vall d Hebron 119 129, 08035 Barcelona, Spain
    Nat Commun 6:8839. 2015
    ..Moreover, CSF ctDNA is shown to facilitate and complement the diagnosis of leptomeningeal carcinomatosis. ..
  26. pmc A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating CDKN1A (p21WAF1/CIP1) degradation
    Rosaura Esteve-Puig
    Animal Models and Cancer Laboratory, Vall d Hebron Research Institute VHIR, Hospital Universitari Vall d Hebron, Barcelona, Spain
    PLoS Genet 10:e1004721. 2014
    ..Altogether, our results identify LKB1 as a DNA damage sensor protein regulating skin UV-induced DNA damage response. ..
  27. doi request reprint Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity
    Aleix Prat
    1 Translational Genomics Group, Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain 2 Breast Cancer Unit, Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain 3 Medical Oncology Department, Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain
    Sci Rep 3:3544. 2013
    ....
  28. pmc Advances in first-line treatment for patients with HER-2+ metastatic breast cancer
    Leticia De Mattos-Arruda
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Oncologist 17:631-44. 2012
    ..Although anti-HER-2 therapy with trastuzumab and chemotherapy is the standard first-line treatment, the best therapeutic regimen has yet to be defined, and new strategies are evolving...
  29. doi request reprint Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP1 and TP53 mutations
    Ana Vivancos
    Cancer Genomics Group Translational Research Program, Vall dHebron Institute of Oncology VHIO, Vall dHebron Hospital, Barcelona, Spain
    Pigment Cell Melanoma Res 29:247-53. 2016
    ..Our results highlight the importance of studying tumor genetic evolution to identify cooperating mechanisms and delineate effective therapies. ..
  30. doi request reprint Therapeutic antibodies in breast cancer
    Jose Perez-Garcia
    Breast Cancer Unit, Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Semin Oncol 41:576-88. 2014
    ..While acknowledging their unquestionable benefit, we emphasize the need to better understand their biology and mechanisms of action in order to optimize their use in defined patient populations. ..
  31. doi request reprint New approach to cancer therapy based on a molecularly defined cancer classification
    Javier Cortes
    Head of the Breast Cancer and Melanoma Programs, Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain Medical Oncologist, Medica Scientia Innovation Research MedSIR, Barcelona, Spain
    CA Cancer J Clin 64:70-4. 2014
    ..Thus, comparisons between tumors residing in different locations but with shared molecular characteristics will improve the therapeutic approach and the understanding of the biology of cancer...
  32. doi request reprint Circulating tumour cells and cell-free DNA as tools for managing breast cancer
    Leticia De Mattos-Arruda
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, 08035 Barcelona, Spain
    Nat Rev Clin Oncol 10:377-89. 2013
    ..In this Review, we discuss the current status of blood-born biomarkers as surrogates for tissue-based biomarkers, and their burgeoning impact on the management of patients with breast cancer. ..
  33. doi request reprint PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition
    Yasir H Ibrahim
    Experimental Therapeutics Laboratory, Vall d Hebron Institute of Oncology VHIO, Pg Vall d Hebron, Barcelona, Spain
    Cancer Discov 2:1036-47. 2012
    ....
  34. doi request reprint Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
    Leticia De Mattos-Arruda
    Medical Oncology Department, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, 08035 Barcelona, Spain
    Breast 21:604-7. 2012
    ..In this article, we revisit HSP90 inhibitors in the context of breast cancer and discuss some notable preclinical data that reveal potential roles in both hormonal receptor-positive and triple negative breast tumor subtypes...
  35. doi request reprint Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study
    Javier Cortes
    Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 15:307-14. 2009
    ....
  36. doi request reprint HER2 and hormone receptor-positive breast cancer--blocking the right target
    Javier Cortes
    Vall d Hebron University Hospital, Oncology Department, Breast Cancer Unit, Paseo Vall d Hebron 119 129, 08035 Barcelona, Spain
    Nat Rev Clin Oncol 8:307-11. 2011
    ..In this article, we highlight the importance of considering chemotherapy and anti-HER2 therapy as the standard of care in HER2-positive and hormone receptor-positive tumors...
  37. pmc Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
    Rocio Vicario
    Preclinical Oncology Program, Vall d Hebron Institute of Oncology VHIO, Universitat Autonoma de Barcelona, 08035, Barcelona, Spain Department of Biochemistry and Molecular Biology, Universitat Autonoma de Barcelona, Campus de la UAB, 08193, Bellaterra, Spain
    PLoS ONE 10:e0129876. 2015
    ..Thus, both clinical and preclinical data show that, despite expectations, loss of HER2 protein expression due to loss of DMs containing HER2 is not a likely mechanism of resistance to anti-HER2 therapies. ..
  38. pmc MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
    Leticia De Mattos-Arruda
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Oncotarget 6:37269-80. 2015
    ....
  39. doi request reprint A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial
    Antonio Llombart-Cussac
    Medica Scientia Innovation Research MedSIR ARO, Barcelona, Spain Hospital Arnau de Vilanova de Valencia, Valencia, Spain Electronic address
    Breast 23:656-62. 2014
    ..Evidence-based definitions of 'poor-prognosis' or 'aggressive' advanced breast cancer are lacking...
  40. doi request reprint Breast-conservative surgery followed by radiofrequency ablation of margins decreases the need for a second surgical procedure for close or positive margins
    Isabel T Rubio
    Breast Surgical Unit, Breast Cancer Center, Vall d Hebron Instituto de Oncología Hospital Universitario Vall d Hebron Universitat Autònoma de Barcelona, Barcelona, Spain Electronic address
    Clin Breast Cancer 14:346-51. 2014
    ..The objective of this study is to analyze the impact of eRFA in avoiding a second surgical procedure for close or positive margins after a breast-conservative surgical procedure...
  41. pmc Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane
    Peter A Kaufman
    Peter A Kaufman, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH Edith A Perez, Mayo Clinic, Jacksonville, FL Martin S Olivo, Yi He, and Corina E Dutcus, Eisai, Woodcliff Lake, NJ Ahmad Awada, Medical Oncology Clinic, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium Chris Twelves and Galina Velikova, Leeds Institute of Cancer and Pathology, and St James s Institute of Oncology, Leeds, United Kingdom Louise Yelle, University of Montreal, Montreal, Quebec, Canada and Javier Cortes, Vall D Hebron University Institute of Oncology, Barcelona, Spain
    J Clin Oncol 33:594-601. 2015
    ..This phase III randomized trial (ClinicalTrials.gov identifier: NCT00337103) compared eribulin with capecitabine in patients with locally advanced or metastatic breast cancer (MBC)...
  42. doi request reprint Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing
    Leticia De Mattos-Arruda
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    Mol Oncol 8:150-8. 2014
    ....
  43. doi request reprint The effect of biology in the treatment of small breast tumors
    Jose Perez-Garcia
    From the Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Medica Scientia Innovation Research MedSIR, Passeig Vall d Hebron, Barcelona, Spain
    Am Soc Clin Oncol Educ Book 33:25-31. 2013
    ..Although a chemotherapy-based strategy might be useful for triple-negative or HER2-positive T1b tumors, more information is urgently needed in order to optimize the treatment of our patients. ..
  44. ncbi request reprint Targeting the microtubules in breast cancer beyond taxanes: the epothilones
    Javier Cortes
    Department of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Oncologist 12:271-80. 2007
    ..The results of these studies are eagerly awaited and it is anticipated that epothilones may become an important treatment option in patients with breast cancer...
  45. ncbi request reprint Prognostic and predictive factors and genetic analysis of early breast cancer
    Miguel Martin
    Department of Medical Oncology, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    Clin Transl Oncol 11:634-42. 2009
    ....
  46. pmc Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
    Eva Muñoz-Couselo
    Breast Cancer Unit, Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Onco Targets Ther 4:185-92. 2011
    ..This review will focus on eribulin as a new active agent for MBC and its role in the management of breast disease...
  47. doi request reprint Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer
    Cristina Saura
    Cristina Saura and Javier Cortés, Vall d Hebron University Hospital, Vall d Hebron Institute of Oncology, Barcelona Jose A Garcia Saenz, Hospital Clinico San Carlos Miguel Martin, Hospital Gregorio Maranon, Universidad Complutense, Madrid, Spain Binghe Xu, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China Wael Harb, Horizon Medical Group, Lafayette, IN Rebecca Moroose, University of Florida Health Cancer Center, Orlando, FL Timothy Pluard, Washington University School of Medicine, St Louis, MO Corinne Kiger, Pfizer Global Research and Development, Paris Caroline Germa, Novartis Pharma, Rueil Malmaison, France Kongming Wang, Pfizer, Pearl River José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY and Sung Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    J Clin Oncol 32:3626-33. 2014
    ....
  48. doi request reprint Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer
    Jose Baselga
    Jose Baselga, Memorial Sloan Kettering Cancer Center, New York, NY Javier Cortés, Vall d Hebron University Hospital, Barcelona, Spain Seock Ah Im, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea Emma Clark and Graham Ross, Roche Products, Welwyn Garden City, United Kingdom Astrid Kiermaier, F Hoffmann La Roche, Basel, Switzerland and Sandra M Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC
    J Clin Oncol 32:3753-61. 2014
    ....
  49. doi request reprint Changes in breast cancer reports after pathology second opinion
    Vicente Marco
    Department of Pathology, Hospital Quiron Barcelona, Barcelona, Spain
    Breast J 20:295-301. 2014
    ....
  50. pmc Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas
    Elena González-Sánchez
    Animal Models and Cancer Laboratory, Anatomy Pathology Department, Vall d Hebron Institut of Research Autonomous University of Barcelona VHIR UAB Barcelona, Barcelona, Spain
    PLoS ONE 8:e66933. 2013
    ..These results posit LKB1 haploinsufficiency as a risk factor for tumor progression of BRAF(V600E) mutated lung adenomas in human cancer patients. ..
  51. doi request reprint Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004
    George Somlo
    City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Clin Cancer Res 19:1884-93. 2013
    ..We aimed to assess toxicity and maximum tolerated dose (MTD) for dasatinib plus capecitabine, estimate efficacy, and explore effects on angiogenesis...
  52. doi request reprint Current situation: lower genital tract pathology and colposcopy training in spanish gynecology and obstetrics residents
    Núria Laia Rodríguez-Mias
    Department of Obstetrics and Gynecology, Hospital Sant Joan de Deu, Universitat de Barcelona, Barcelona, Spain
    J Low Genit Tract Dis 17:12-6. 2013
    ..This didactic change was carried out under the auspices of the Asociación Española de Patología Cervical y Colposcopia and the Sociedad Española Ginecología y Obstetricia and its Resident Section...
  53. ncbi request reprint Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors
    Eduardo Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona 08035, Spain
    Endocr Relat Cancer 14:221-32. 2007
    ..Also a comprehensive review of the literature about chemotherapy in NETs is presented...
  54. doi request reprint Molecular pathways: targeting hsp90--who benefits and who does not
    Maurizio Scaltriti
    Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA
    Clin Cancer Res 18:4508-13. 2012
    ..Several ongoing studies testing different combinations of Hsp90 inhibitors with other targeted agents will confirm whether Hsp90 inhibition can potentiate the efficacy of targeted therapy and/or prevent the emergence of drug resistance...
  55. doi request reprint Hepatic resection for liver metastases as part of the "oncosurgical" treatment of metastatic breast cancer
    Mireia Caralt
    Department of Hepatobiliopancreatic Surgery and Transplants, Hospital Universitari Vall d Hebron, Paseo Vall d Hebron119 129, Barcelona, 08035, Spain
    Ann Surg Oncol 15:2804-10. 2008
    ..Metastatic breast cancer is considered an incurable disease despite new therapies. Recent studies suggest that liver resection associated with systemic treatment may improve patient survival...
  56. pmc Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
    Maurizio Scaltriti
    Departments of Medical Oncology and Molecular Pathology, Vall d Hebron Institute of Oncology, 08035 Barcelona, Spain
    Proc Natl Acad Sci U S A 108:3761-6. 2011
    ....